Abstract:The swine industry across the globe is recently facing a devastating situation imparted by a highly contagious and deadly viral disease, African swine fever. The disease is caused by a DNA virus, the African swine fever virus (ASFV) of the genus Asfivirus . ASFV affects both wild boars and domestic pigs resulting in an acute form of hemorrhagic fever. Since the first report in 1921, the disease remains endemic in some of the African countries. However, the recent occurrence of ASF outbreaks in Asia led to a fresh and formidable challenge to the global swine production industry. Culling of the infected animals along with the implementation of strict sanitary measures remains the only options to control this devastating disease. Efforts to develop an effective and safe vaccine against ASF began as early as in the mid-1960s. Different approaches have been employed for the development of effective ASF vaccines including inactivated vaccines, subunit vaccines, DNA vaccines, virus-vectored vaccines, and live attenuated vaccines (LAVs). Inactivated vaccines are a non-feasible strategy against ASF due to their inability to generate a complete cellular immune response. However genetically engineered vaccines, such as subunit vaccines, DNA vaccines, and virus vector vaccines, represent tailored approaches with minimal adverse effects and enhanced safety profiles. As per the available data, gene deleted LAVs appear to be the most potential vaccine candidates. Currently, a gene deleted LAV (ASFV-G-∆I177L), developed in Vietnam, stands as the sole commercially available vaccine against ASF. The major barrier to the goal of developing an effective vaccine is the critical gaps in the knowledge of ASFV biology and the immune response induced by ASFV infection. The precise contribution of various hosts, vectors, and environmental factors in the virus transmission must also be investigated in depth to unravel the disease epidemiology. In this review, we mainly focus on the recent progress in vaccine development against ASF and the major gaps associated with it.

Current efforts towards safe and effective live attenuated vaccines against African swine fever: challenges and prospects

African swine fever control and prevention: an update on vaccine development

Attenuated African swine fever viruses and the live vaccine candidates: a comprehensive review

Vaccines for African swine fever: an update

Summary of the Current Status of African Swine Fever Vaccine Development in China

Progress Toward Development of Effective and Safe African Swine Fever Virus Vaccines

Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus

Recent progress and major gaps in the vaccine development for African swine fever

ASFV subunit vaccines: Strategies and prospects for future development

Current State of Global African Swine Fever Vaccine Development under the Prevalence and Transmission of ASF in China

Recent progress on gene-deleted live-attenuated African swine fever virus vaccines

Advancement in the development of gene/protein-based vaccines against African swine fever virus

Challenging boundaries: is cross-protection evaluation necessary for African swine fever vaccine development? A case of oral vaccination in wild boar

Taking a Promising Vaccine Candidate Further: Efficacy of ASFV-G-ΔMGF after Intramuscular Vaccination of Domestic Pigs and Oral Vaccination of Wild Boar

Advancement in the Antigenic Epitopes and Vaccine Adjuvants of African Swine Fever Virus

A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus

Evaluation of the Safety Profile of the ASFV Vaccine Candidate ASFV-G-ΔI177L

Challenges in the Application of African Swine Fever Vaccines in Asia

Regulation of Antiviral Immune Response by African Swine Fever Virus (ASFV).

A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs